This post is from a low-reputation account and contains an unverified outbound link. Be cautious before clicking external links.
Type 2 diabetes mellitus (T2DM), a chronic metabolic condition, is distinguished by high blood sugar and insulin resistance. One significant advancement in the treatment of T2DM over the years is the creation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. The sodium-glucose cotransporter-2 proteins in the kidneys are the target of a class of oral diabetic medications known as SGLT-2 inhibitors.